# USPTO Electronic Acknowledgement Receipt

**Receipt Date/Time:** 10/02/2025 10:41:02 AM Z ET
**Application Number:** 63/892,131
**Attorney Docket Number:** 60885-756.101

**Title of Invention:** COMPOSITIONS, METHODS, AND SYSTEMS FOR CONTROLLING COMPLEX MOLECULE SUBUNIT EXPRESSION

**Application Information:**
* **Application Type:** Utility - Provisional Application under 35 USC 111(b)
* **Confirmation #:** 3433
* **Patent Center #:** 72555976
* **Customer #:** 21971

**Filing Information:**
* **Filed By:** Brenda MacLean
* **Authorized By:** Victor JONES, In Young Choi

### Documents Filed

| Document | Pages | Description | Size (KB) |
| :--- | :--- | :--- | :--- |
| ADS.pdf | 9 | Application Data Sheet | 2179 KB |
| 60885-756.101 Spec_Ratiometric Control-SPEC.pdf | 73 (1-73) | Specification | 368 KB |
| 60885-756.101 Spec_Ratiometric Control-CLM.pdf | 12 (74-85) | Claims | 147 KB |
| 60885-756.101 Spec_Ratiometric Control-ABST.pdf | 1 (86-86) | Abstract | 87 KB |
| Prolific Machines 60885-756.101 Drawings 17 PGS.pdf | 17 | Drawings-only black and white line drawings | 1816 KB |
| Prolific 60885-756.101 POA.pdf | 2 | Power of Attorney | 221 KB |

### Payment Information

* **Payment Method:** Pre-Authorized Account (232415)
* **Payment Authorized By:** Brenda MacLean
* **Transaction ID:** E202502A42138407
* **Fee Code 1005:** Provisional Application Filing Fee ($325.00)
* **Total Amount:** $325.00

---

# Application Data Sheet 37 CFR 1.76

**Attorney Docket Number:** 60885-756.101
**Title of Invention:** COMPOSITIONS, METHODS, AND SYSTEMS FOR CONTROLLING COMPLEX MOLECULE SUBUNIT EXPRESSION

### Inventor Information

**Inventor 1:**
* **Name:** Victor JONES
* **Residence:** Berkeley, CA, US
* **Mailing Address:** 6400 Hollis Street, Emeryville, CA 94608 US

**Inventor 2:**
* **Name:** Shahram MISAGHI
* **Residence:** Oakland, CA, US
* **Mailing Address:** 6400 Hollis Street, Emeryville, CA 94608 US

**Inventor 3:**
* **Name:** Maximilian HÃ–RNER
* **Residence:** Emeryville, CA, US
* **Mailing Address:** 6400 Hollis Street, Emeryville, CA 94608 US

### Correspondence Information
* **Customer Number:** 21971
* **Email:** patentdocket@wsgr.com

### Application Information
* **Title:** COMPOSITIONS, METHODS, AND SYSTEMS FOR CONTROLLING COMPLEX MOLECULE SUBUNIT EXPRESSION
* **Attorney Docket Number:** 60885-756.101
* **Application Type:** Provisional
* **Subject Matter:** Utility
* **Total Drawing Sheets:** 17

### Applicant Information
* **Organization:** Prolific Machines Inc.
* **Mailing Address:** 6400 Hollis Street, Emeryville, CA 94608 US

### Authorization
The undersigned grants the USPTO authority to provide the EPO, JPO, KIPO, SIPO, WIPO, and other participating offices access to the instant patent application-as-filed.

### Signature
* **Name:** In Young Choi
* **Registration Number:** 80,724
* **Date:** 2025-10-02

---

# Specification

**Title:** COMPOSITIONS, METHODS, AND SYSTEMS FOR CONTROLLING COMPLEX MOLECULE SUBUNIT EXPRESSION

## Background
[0001] Multimeric proteins comprising multiple subunits play essential roles. Multimeric proteins can comprise homomeric assemblies of identical subunits or heteromeric assemblies of distinct polypeptide chains. These complexes are critical for diverse functions. Recombinant protein production for multimeric proteins can be challenging in research, industrial manufacturing, and biopharmaceutical development.

## Summary
[0002] To effectively express complex molecules (e.g., multimeric proteins) in cell lines, genetic vectors containing coding regions that are transfected into the cells can be used. For multimeric proteins, it is often unclear which specific subunits of these molecules will be the limiting factor in achieving the necessary stoichiometric balance and proper configuration among all the subunits involved. The expression of complex molecules can be managed using expression vectors, designed to control the transcription and translation of target genes (vector configuration). However, the challenge lies in the sheer number of different vector configurations/combinations to be tested.

[0003] One powerful technique that has emerged in this field is optogenetics, which employs light-sensitive proteins (or light-responsive proteins) to precisely modulate the activity of a protein-of-interest under specific light-responsive promoter unit. This approach enables the regulation of expression of transfected coding regions of complex molecules, offering a high degree of control over gene expression.

[0004] The present disclosure provides methods, compositions, and systems for controlling complex molecule (e.g., multimeric polypeptide) subunit expression through cell line development processes and optogenetic expression controls. By utilizing both optogenetic and constitutive expression systems in a combinatorial barcoded vector design, control and optimization of specific complex molecule subunit expression levels can be achieved.

[0005] In some aspects, provided herein is a system for producing a multimeric polypeptide complex comprising a plurality of polypeptide subunits. This comprises a first polynucleotide sequence encoding a first polypeptide subunit operably coupled to a first promoter unit; and a second polynucleotide sequence encoding the first polypeptide subunit operably coupled to a second and different promoter unit. In some embodiments, the first promoter unit comprises an optogenetic promoter unit, and the second comprises a constitutive promoter.

[0006] In some aspects, provided herein is a system for producing a multimeric polypeptide complex comprising: a first polynucleotide sequence encoding a first polypeptide subunit operably coupled a first optogenetic promoter unit that responds to a first light; and a second polynucleotide sequence encoding the first polypeptide subunit operably coupled to a first constitutive promoter. The expression level of the first polypeptide subunit is regulated by modulating exposure of the system to the first light.

[0007] Provided herein is a system for producing a multimeric polypeptide complex comprising: a first polynucleotide sequence encoding a first polypeptide subunit operably coupled to a first optogenetic promoter unit; and a second polynucleotide sequence encoding a second polypeptide subunit operably coupled to a second optogenetic promoter unit.

[0008] In some aspects, provided herein is a system for producing a multimeric polypeptide complex comprising a plurality of polypeptide subunits, the system comprising: a first polynucleotide molecule encoding at least two copies of a first polypeptide subunit of the plurality; and a second and different polynucleotide molecule encoding at least one copy of a second and different subunit of the plurality.

## Detailed Description
[0033] In some aspects, provided herein are methods, compositions, and systems for producing complex molecules. Controlling the expression levels of individual subunits of a complex molecule may be desirable. In some cases, individual subunits can be rate-limiting for correct assembly or expressed in excess.

### Multimeric Polypeptide Complex
[0035] In some aspects, provided herein is methods, compositions, and systems for producing a multimeric polypeptide complex. The complex may comprise at least one, at least two, at least three, at least four, at least five, at least six, or more subunits.

[0036] As used herein, a "promoter unit" may refer to a nucleic acid construct that directs transcription of an operably linked nucleic acid sequence. In some cases, the promoter unit may comprise a constitutive promoter. In some cases, the promoter unit may direct transcription in response to a regulatory factor (e.g., light-controllable transcriptional activators).

[0048] In some embodiments, a multimeric polypeptide complex can comprise an antibody or fragment thereof or an immune complex. Antibodies can cover a vast array of formats including but not limited to: Fab fragments, F(ab')2 fragments, Fv fragments, scFv, BsAb, trispecific antibodies, diabodies, DVD-Ig, VHH domains, and nanobodies.

### Gene Regulations & Promoter Units
[0051] Table 1 provides non-limiting examples of constitutive promoters and minimal promoters.

**Table 1. Non-limiting exemplary promoters**

| Category | Promoter Name |
| :--- | :--- |
| **Constitutively Active Promoters** | CMV (Cytomegalovirus immediate early) |
| | EF1a (Elongation factor 1-alpha) |
| | CAG (CMV enhancer-chicken beta-actin-rabbit beta-globin hybrid) |
| | UbC (Human ubiquitin C) |
| | PGK (Phosphoglycerate kinase) |
| **Minimal Promoters** | TATA box minimal promoter |
| | minCMV (Minimal CMV) |
| | minTK (Minimal thymidine kinase) |
| | minSV40 (Minimal simian virus 40) |
| | Adenovirus Major Late Promoter (MLP) |
| | YB TATA |
| | TATA box alone |
| | MinSyns |
| | H1-corem |

[0052] Table 2 provides nonlimiting exemplary DNA-binding recognition elements and its cognate DNA binding domain.

**Table 2. Non-limiting exemplary DNA-recognition sequence and corresponding DNA-binding domains**

| DNA Binding Recognition Element | Cognate DNA-Binding Domain (Protein) |
| :--- | :--- |
| Upstream Activating Sequence of Gal4 (UAS-Gal4) | Gal4 |
| LexA operator (LexO) | LexA DNA-binding domain |
| Tet operator (TetO) | Tetracycline repressor (TetR) or reverse Tet transactivator (rtTa) |
| Lac operator (Laco) | Lacl repressor |
| Octamer motif | Oct-1/Oct-4 POU homeodomain protein |
| E-bx | bHLH transcription factor |
| cAMP response element (CRE) | cAMP response element-binding protein (CREB) |
| Androgen response element (ARE) | Androgen receptor DNA-binding domain |
| Estrogen response element (ERE) | Estrogen receptor DNA-binding domain |
| NF-kB response element | NF-kB p65/p50 |
| SP1 binding site | SP1 zinc finger transcription factor |
| EthR binding site | EthR |
| C120 | Helix-turn-helix (HTH) domain |

[0058] Non-limiting examples of optogenetic dimerization systems suitable for use with the methods and systems provided herein are described in Table 3.

**Table 3. Non-limiting examples of light-controllable protein systems**

| System | Binding type | Light-controllable protein 1 | Light-controllable protein 2 | Light |
| :--- | :--- | :--- | :--- | :--- |
| BICYCL | Heterodimer | Am1 c0023g2 | BAm-green or BAm-red | Am1 c0023g2 interacts in the dark or under green light with BAm-red and dissociates under red light. |
| Blue-light-using FAD (BLUF) photoreceptor domain | heterooligomerization | PixD | PixD | Blue light results in heterooligomerization |
| Cobalamin binding domains (CBD) | oligomer | CBD | | Homooligomerizes in dark; green light results in dissociation |
| Cph1 | homodimer | Cph1 | | Red light induces homodimerization. Dissociation under far-red light. |
| cpLID | heterodimer | SsrA-cpLOV2 | SspB | Blue light results in dimerization |
| cpLOVTRAP | heterodimer | cpLOV2 | Zdk2 | Blue light results in dimerization |
| CRY-CIBN | heterodimer | PHR domain | CIBN | Blue light results in dimerization |
| Cryptochrome (CRY) | Homodimer/oligomer | Photolyase-Homologous Region (PHR) domain | | Blue light results in dimerization and oligomerization |
| DrBphP1/PpsR2 | heterodimer | BphP1 | PpsR2 or QPAS-1 | Near infrared light results in dimerization; red light dissociates |
| Dronpa | homodimer | Dronpa | | Illumination with blue light results in monomerization; illumination with UV light results in dimerization |
| EL222 | Homodimer | EL222 | | Blue light results in dimerization |
| FKF1/GI | heterodimer | FKF1 | GI | Blue light results in dimerization |
| iLID | heterodimer | ASLOV2-SsrA | SspB | Blue light results in dimerization |
| IsPadC-PCM | Homodimer | IsPadC-PCM | | Red light results in dimerization, far red light results in dissociation |
| LOVTRAP | heterodimer | ASLOV2 | Zdk | Blue light results in dimerization |
| Magnets | heterodimer | pMag | nMag | Blue light results in dimerization |
| MagRed | Heterodimer | DrBphP | Aff6 V18FAN | Red light results in dimerization, far red light results in dissociation |
| nanoReD | Heterodimer | DrBphP | LDB Nanobody | Red light results in dimerization, far red light results in dissociation |
| PhoCl | Light-induced cleavage | PhoCl | | UV light induces cleavage of PhoCl |
| PhyA | heterodimer | PhyA | FHY1, FHL | Red light results in dimerization, far red light results in dissociation |
| PhyB | heterodimer | PhyB | PIF (PIF3, PIF6) | Red light results in dimerization, far red light results in dissociation |
| PtAU1-LOV | Homodimer | PtAU1-LOV | | Blue light results in dimerization |
| RSLOV | Homodimer | RSLOV | | Blue light results in dissociation of homodimer |
| TULIP | heterodimer | ASLOV2-ePDZpeptide | ePDZ | Blue light results in dimerization |
| UVR8 | homodimer | UVR8 | | Dissociates when exposed to UV-B light |
| UVR8 | heterodimer | UVR8 | COP1 | UVR8 homodimer dissociates when exposed to UV-B light and forms heterodimer with COP1 |
| VfAU1 | Homodimer | VfAU1-LOV | | Blue light results in dimerization |
| VVD | Homodimer | VVD | | Blue light results in dimerization |

[0062] In some embodiments, a light-controllable protein described herein is a hybrid system. For example, the Gal4-VP16-LOV (GAVPO) transcription factor.

### Light
[0135] In various aspects, the methods involve modulating the exposure of a system to a light at a particular wavelength. The wavelength of light may be one or more of infrared, near infrared, visible light (e.g., red, green, blue), ultraviolet light, or a combination thereof.
* Infrared: ~780 nm to 1 mm
* Near infrared: ~740 nm to 780 nm
* Red: ~620 nm to 750 nm
* Green: ~577 nm to 492 nm
* Blue: ~492 to 455 nm

### Examples
**Example 1: Using a single light inducible Opto system to ratiometrically control expression of one or more chains in a bispecific antibody**
[0181] Six distinct vector constructs are generated for transfection into CHO cells. The three heavy chain expressing vectors (Fc-1, Fc-2, and Fc-3) contain a first selection marker, and the three light chain expressing vectors (Fab-1, Fab-2, and Fab-3) contain a different selection marker.

**Example 2: Using different strength Opto promoters responsive to different lights**
[0190] Eight vector constructs, four heavy chain expressing vectors and four light chain expressing vectors, are generated. The two different opto promoters (1 and 2) are responsive to different lights.

---

# Claims

1.  [cite_start]A system for producing a multimeric polypeptide complex comprising a plurality of polypeptide subunits, comprising: a first polynucleotide sequence encoding a first polypeptide subunit of the multimeric polypeptide complex operably coupled to a first promoter unit; and a second polynucleotide sequence encoding the first polypeptide subunit of the multimeric polypeptide complex operably coupled to a second and different promoter unit. [cite: 1784-1787]
2.  The system of claim 1, wherein the first promoter unit comprises an optogenetic promoter unit.
3.  The system of claim 1 or 2, wherein the second promoter unit comprises a constitutive promoter.
4.  The system of any one of the preceding claims, wherein the system further comprises a third polynucleotide sequence encoding a second polypeptide subunit of the multimeric protein complex operably coupled to a third promoter unit.
5.  The system of claim 4, wherein the third promoter unit comprises a constitutive promoter.
6.  The system of claim 4, wherein the third promoter unit comprises an optogenetic promoter unit.
7.  The system of any one of the preceding claims, wherein the system further comprises a fourth polynucleotide sequence encoding a third polypeptide subunit of the multimeric protein complex operably coupled to a fourth promoter unit.
8.  The system of claim 5, wherein the fourth promoter unit comprises a constitutive promoter.
9.  The system of claim 5, wherein the fourth promoter unit comprises an optogenetic promoter unit.
10. The system of any one of the preceding claims, wherein the system further comprises a fifth polynucleotide sequence encoding a fourth polypeptide subunit of the multimeric protein complex operably coupled to a fifth promoter unit.
11. The system of claim 10, wherein the fifth promoter unit comprises a constitutive promoter.
12. The system of claim 10, wherein the fifth promoter unit comprises an optogenetic promoter unit.
13. The system of any one of the preceding claims, wherein expression level of the first polypeptide subunit is regulated by modulating exposure of the system to a first light comprising a first wavelength or wavelength range.
14. [cite_start]A system for producing a multimeric polypeptide complex comprising: a first polynucleotide sequence encoding a first polypeptide subunit of the multimeric polypeptide complex operably coupled a first optogenetic promoter unit that responds to a first light comprising a first wavelength or a wavelength range; and a second polynucleotide sequence encoding the first polypeptide subunit of the multimeric polypeptide complex operably coupled to a first constitutive promoter, a third polynucleotide sequence encoding a second polypeptide subunit of the multimeric polypeptide complex operably coupled to a second optogenetic promoter unit that responds to a second light comprising a second wavelength or a wavelength range; wherein expression level of the first polypeptide subunit is regulated by modulating exposure of the system to the first light; and wherein expression level of the second subunit is modulated by modulating exposure of the system to the second light. [cite: 1813-1821]
15. The system of claim 14, wherein the first light comprising the first wavelength or the wavelength range and the second light comprising the second wavelength or the wavelength range are the same.
16. The system of claim 14, wherein the first light comprising the first wavelength or the wavelength range and the second light comprising the second wavelength or the wavelength range are different.
17. The system of claim 16, wherein the first light comprising the first wavelength or the wavelength range is nonoverlapping with the second light comprising the second wavelength or the wavelength range.
18. The system of any one of the preceding claims, wherein the system further comprises a fourth polypeptide sequence encoding the second polypeptide subunit of the multimeric polypeptide complex operably coupled to a constitutive promoter.
19. The system of any one of the preceding claims, wherein the system further comprises a fifth polynucleotide sequence encoding a third polypeptide subunit operably coupled to a promoter unit.
20. The system of claim 19, wherein the promoter unit comprises a constitutive promoter.
21. The system of claim 19, wherein the promoter unit comprise an optogenetic promoter unit.
22. The system of any one of the preceding claims, wherein the system further comprises a sixth polynucleotide sequence encoding a fourth polypeptide subunit operably coupled to a promoter unit.
23. The system of claim 22, wherein the promoter unit comprises a constitutive promoter.
24. The system of claim 22, wherein the promoter unit comprises an optogenetic promoter unit.
25. The system of any one of the preceding claims, wherein the first polypeptide subunit, the second polypeptide subunit, the third polypeptide subunit and/or the fourth polypeptide subunit form at least a portion of the multimeric polypeptide complex.
26. The system of any one of the preceding claims, wherein the first polypeptide subunit, the second polypeptide subunit, the third polypeptide subunit, and/or the fourth polypeptide subunit are identical polypeptide subunits of the multimeric polypeptide complex.
27. The system of any one of the preceding claims, wherein the first polypeptide subunit, the second polypeptide subunit, the third polypeptide subunit, and/or the fourth polypeptide subunit are different polypeptide subunits of the multimeric polypeptide complex.
28. The system of any one of the preceding claims, wherein the system further comprises a first expression construct comprising the first polynucleotide sequence and the second polynucleotide sequence.
29. The system of claim 28, wherein the first expression construct further comprises the third polynucleotide sequence, the fourth polynucleotide sequence, the fifth polynucleotide sequence, and/or the sixth polynucleotide sequence.
30. The system of claim 28, wherein the system further comprises a second expression construct comprising the third polynucleotide sequence, the fourth polynucleotide sequence, the fifth polynucleotide sequence, and/or the sixth polynucleotide sequence.
31. The system of any one of the preceding claims, wherein a first expression construct comprises the first polynucleotide sequence and the second polynucleotide sequence, wherein the first polypeptide subunit is part of a first polypeptide molecule, and wherein the system comprises a second and different expression construct encoding at least a portion of the second polypeptide molecule.
32. [cite_start]A system for producing a multimeric polypeptide complex comprising: a first polynucleotide sequence encoding a first polypeptide subunit of the multimeric polypeptide complex operably coupled to a first optogenetic promoter unit that responds to a first light comprising a first wavelength or a wavelength range; and a second polynucleotide sequence encoding a second polypeptide subunit of the multimeric polypeptide complex operably coupled to a second optogenetic promoter unit that responds to a second light comprising a second wavelength or a wavelength range, wherein expression level of the first polypeptide subunit is regulated by modulating exposure of the system to the first light, and wherein expression level of the second polypeptide subunit is regulated by modulating exposure of the system to the second light. [cite: 1842-1846]
33. The system of any one of the preceding claims, wherein the first optogenetic promoter unit and the second optogenetic promoter unit are the same.
34. The system of any one of the preceding claims, wherein the first optogenetic promoter unit and the second optogenetic promoter unit are different.
35. The system of claim 33 or 34, wherein the first optogenetic promoter unit and the second optogenetic promoter unit have different promoter strengths.
36. The system of claim 35, wherein the first optogenetic promoter drives stronger expression of the first polypeptide subunit relative to expression of the second polypeptide subunit by the second optogenetic promoter unit.
37. The system of claim 35, wherein the second optogenetic promoter unit drives stronger expression of the second polypeptide subunit relative to expression of the first polypeptide subunit by the first optogenetic promoter unit.
38. The system of claim 33 or 34, wherein the first optogenetic promoter unit and the second optogenetic promoter unit are responsive to different light stimuli.
39. The system of claim 38, wherein the first light and the second light are the same.
40. The system of claim 38, wherein the first light and the second light are different.
41. The system of claim 33 or 34, wherein the first optogenetic promoter unit and the second optogenetic promoter unit have different activation kinetics
42. The system of claim 41, wherein the first optogenetic promoter unit drives expression of the first polypeptide subunit with a shorter activation time relative to expression of the second polypeptide subunit by the second optogenetic promoter unit.
43. The system of claim 41 or 42, wherein the second optogenetic promoter unit drives expression of the second polypeptide subunit with a shorter activation time relative to expression of the first polypeptide subunit by the first optogenetic promoter unit.
44. The system of any one of claims 32-43, wherein the system further comprises a third polynucleotide sequence encoding the first polypeptide subunit of the multimeric polypeptide complex operably coupled to a constitutive promoter.
45. The system of any one of claims 32-44, wherein the system further comprises a fourth polynucleotide sequence encoding the second polypeptide subunit of the multimeric polypeptide complex operably coupled to a constitutive promoter.
46. The system of any one of claims 32-45, wherein the system further comprises a fifth polynucleotide sequence encoding a third polypeptide subunit operably coupled to a promoter unit.
47. The system of claim 46, wherein the promoter unit comprises a constitutive promoter.
48. The system of claim 46, wherein the promoter unit comprises an optogenetic promoter unit.
49. The system of any one of the preceding claims, wherein the system further comprises a sixth polynucleotide sequence encoding a fourth polypeptide subunit operably coupled to a promoter unit.
50. The system of claim 49, wherein the promoter unit comprises a constitutive promoter.
51. The system of claim 49, wherein the promoter unit comprises an optogenetic promoter unit.
52. The system of any one of claims 35-51, wherein the system comprises a first expression construct comprising the first polynucleotide sequence and the second polynucleotide sequence.
53. The system of claim 52, wherein the first expression construct further comprises the third polynucleotide sequence, the fourth polynucleotide sequence, the fifth polynucleotide sequence, and/or the sixth polynucleotide sequence.
54. The system of claim 52, wherein the system comprises a second expression construct comprising the third polynucleotide sequence, the fourth polynucleotide sequence, the fifth polynucleotide sequence, and/or the sixth polynucleotide sequence.
55. The system of any one of claims 32-51, wherein the system comprises a first expression construct comprising the first polynucleotide sequence and a second expression construct comprising the second polynucleotide sequence.
56. The system of claim 55, wherein the first expression construct further comprises the third polynucleotide sequence.
57. The system of claim 55, wherein the second expression construct further comprises the fourth polynucleotide sequence.
58. The system of any one of claims 55-57, wherein the first expression construct further comprises the fifth polynucleotide sequence and/or the sixth polynucleotide sequence.
59. The system of any one of claims 55-58, wherein the second expression construct further comprises the fifth polynucleotide sequence and/or the sixth polynucleotide sequence.
60. The system of any one of the preceding claims, wherein the first expression construct and/or second expression construct comprises a barcode.
61. The system of any one of the preceding claims, wherein the first expression construct and/or the second expression construct comprises a selection marker.
62. The system of any one of the preceding claims, wherein the first expression construct comprises a first selection marker.
63. The system of any one of the preceding claims, wherein the second expression construction comprises a second and different selection marker.
64. The system of any one of the preceding claims, wherein the modulating comprises initiating the exposure of the cell to the first light and/or the second light.
65. The system of any one of the preceding claims, wherein the modulating comprises terminating the exposure of the cell to the first light and/or the second light.
66. The system of any one of the preceding claims, wherein the modulating comprises changing one or more illumination parameters of the first light and/or the second light while the cell is under exposure to the first light and/or the second light.
67. The system of any one of the preceding claims, wherein the system further comprises: one or more optical sources configured to generate the first light and/or the second light; and a processor configured to direct the one or more optical sources to generate the first light.
68. The system of claim 67, wherein the one or more optical sources are configured to generate the second light.
69. The system of claim 68, wherein the one or more optical sources are configured to generate the second light prior to the first light.
70. The system of claim 68, wherein the one or more optical sources are configured to generate the second light simultaneously with the first light.
71. The system of claim 68, wherein the one or more optical sources are configured to generate the second light after the first light.
72. The system of any one of claims 67-71, wherein the processor is configured to adjust one or more light parameters.
73. The system of claim 72, wherein the one or more illumination parameters comprises the illumination pattern, wherein the illumination pattern is a pulsing pattern, a sinusoidal pattern, a linear pattern, a blinking pattern, or any combination thereof.
74. The system of claim 72, wherein the processor is configured to adjust a duration of the first light and/or the second light.
75. The system of any one of claims 72-74, wherein the processor is configured to adjust a pattern in which the first light and/or the second light is generated.
76. The system of any one of claims 72-75, wherein the processor is configured to adjust an intensity at which the first light and/or the second light is generated.
77. The system of any one of claims 72-75, wherein the processor is configured to adjust a wavelength of the first light and/or the second light.
78. The system of any one of the preceding claims, wherein the first light is different from the second light by at least or at most about 1 nanometer, at least or at most about 2 nanometers, at least or at most about 5 nanometers, at least or at most about 10 nanometers, at least or at most about 20 nanometers, at least or at most about 30 nanometers, at least or at most about 40 nanometers, at least or at most about 50 nanometers, at least or at most about 100 nanometers, at least or at most about 200 nanometers, at least or at most about 300 nanometers, at least or at most about 400 nanometers, or at least or at most about 500 nanometers.
79. The system of any one of the preceding claims, wherein at least one of the first polypeptide subunit, the second polypeptide subunit, the third polypeptide subunit, and/or the fourth polypeptide subunit of the multimeric polypeptide comprises an antigen binding domain.
80. The system of claim 79, wherein the multimeric polypeptide protein is an antibody or a fragment thereof.
81. The system of claim 80, wherein the antibody comprises a Fab, a F(ab')2, an Fv, a single chain Fv (scFv), a single domain antibody, a bispecific antibody (BsAb), a trispecific antibody, a diabody (dAb), dual variable domain antibodies (DVD-Ig), a VHH, a camelid antibody, a nanobody, an IgG-like engineered antibody, an IgM antibody, an IgA antibody, an IgE antibody, an IgD antibody, a hexabody, a bispecific T-cell engager (BiTE), a dual affinity retargeting molecule (DART), a fragment thereof, or any combination thereof.
82. The system of any one of the preceding claims, wherein each optogenetic promoter unit comprises a DNA recognition sequence.
83. The system of any one of the preceding claims, wherein each optogenetic promoter unit comprises a promoter.
84. The system of claim 83, wherein the promoter is a minimal promoter.
85. The system of claim 84, wherein the minimal promoter is operably linked to the DNA-recognition sequence.
86. The system of any one of the preceding claims, wherein the system further comprises one or more light-controllable transcriptional regulators that interact (e.g., directly or indirectly) with the DNA recognition sequence of the first optogenetic promoter unit and/or the second optogenetic promoter unit.
87. The system of claim 86, wherein the first light or the second light is sufficient to regulate the interaction of the one or more light-controllable transcriptional regulators with the DNA recognition sequence of the first optogenetic promoter unit and/or the second optogenetic promoter unit to control the expression of the first polypeptide subunit and/or the expression of the second polypeptide subunit.
88. The system of claim 86 or 87, wherein the one or more light-controllable transcriptional regulators are one or more light-controllable transcriptional activators or one or more light-controllable transcriptional repressors.
89. The system of claim 88, wherein the one or more light-controllable transcriptional activators comprise a light-controllable protein coupled to (e.g., directly or indirectly) a transcriptional activator.
90. The system of claim 88, wherein the one or more light-controllable transcriptional repressors comprise a light-controllable protein coupled to (e.g., directly or indirectly) a transcriptional repressor.
91. The system of claim 89 or 90, wherein the light-controllable protein comprises EL222, Light-Oxygen-Voltage (LOV) Domain, PhyB-PIF, PhyA-PIF, PhyA-FHY1, PhyA-FHL, UVR8-COP1, VVD, Blue-light-using FAD (BLUF) photoreceptor domain, Dronpa, Dronpa145N, Deinococcus radiodurans bacterial phytochrome (DrBphP), MagRed, NanoRed, Cobalamin binding domains (CBD), CRY2/CIB1 unit, CRY2-Olig, Opto-Cas, Opti-dCas, BphP1-QPAS1, BphS/BphO unit, Cph1, Cph8, or OptoXRs.
92. The system of claim 91, wherein the light-controllable protein is coupled to (e.g., directly or indirectly) a transcriptional effector.
93. The system of claim 92, wherein the transcriptional effector comprises VP16, VP64, VPR, p65, Rta, SAM, KRAB, SID, REST/NTSF, HDAC, or a combination thereof.
94. [cite_start]A system for producing a multimeric polypeptide complex comprising a plurality of polypeptide subunits, the system comprising: a first polynucleotide molecule encoding at least two copies of a first polypeptide subunit of the plurality; and a second and different polynucleotide molecule encoding at least one copy of a second and different subunit of the plurality. [cite: 1937-1940]
95. The system of claim 94, wherein the first polynucleotide molecule and the second polynucleotide molecules are different expression vectors.
96. The system of claim 94 or 95, wherein, in the first polynucleotide molecule, the at least two copies of the first polypeptide subunit are under the control of different promoters.
97. The system of claim 94 or 95, wherein, in the first polynucleotide molecule, the at least two copies of the first polypeptide subunit are under the control of a same promoter.
98. The system of any one of claims 94-97, wherein, in the first polynucleotide molecule, at least one of the at least two copies of the first polypeptide subunit is under the control of an optogenetic promoter.
99. The system of any one of claims 94-97, wherein the other copy of the at least two copies of the first polypeptide subunit is under the control of a constitutive promoter.
100. The system of any one of claims 94-99, wherein the second polynucleotide molecule encodes at least two copies of the second subunit.
101. The system of any one of claims 94-99, wherein the second polynucleotide molecule encodes only a single copy of the second subunit.
102. The system of any one of claims 94-101, wherein the first polynucleotide molecule encodes at least one copy of a third polypeptide subunit of the plurality.
103. The system of claim 102, wherein the first polynucleotide molecule encodes at least one copy of a third polypeptide subunit of the plurality.
104. The system of any one of claims 94-101, wherein the first polynucleotide molecule encodes only a single copy of the third polypeptide subunit.
105. The system of any one of claims 94-104, wherein the first polynucleotide molecule, the second polynucleotide molecule, or both comprise (i) a barcode or (ii) a selection marker.
106. The system of any one of claims 94-105, wherein the multimeric polypeptide complex is a heterodimer, heterotrimer, or heterotetrametric
107. The system of any one of claims 94-106, wherein the multimeric polypeptide complex comprises a therapeutic protein complex.
108. The system of any one of claims 94-107, wherein the multimeric polypeptide complex comprises an antibody, a fragment thereof, or a variant thereof.
109. The system of any one of claims 94-108, wherein the first polypeptide subunit comprises at least a portion of a heavy chain of the antibody, and wherein the second polypeptide subunit comprises at least a portion of a light chain of the antibody.
110. A cell comprising the system of any one of claims 1-109.
111. The cell of claim 110, wherein the cell is a eukaryotic cell.
112. The cell of claim 111, wherein the cell is a mammalian cell, an insect cell, a plant cell, or a yeast.
113. The cell of any one of claims 110-112, wherein the cell is a suspension adapted cell.
114. The cell of any one of claims 110-113, wherein the cell is HEK, CHO, HELA, NS0, NIH-3T3, or COS-7.
115. A cell culture comprising the cell of any one of claims 110-114.
116. A bioreactor comprising the cell culture of claim 116.
117. A method for producing a multimeric polypeptide complex comprising a plurality of polypeptide subunits, the method comprising: contacting one or more cells with the system of any one of the preceding claims, to express the multimeric polypeptide complex in the one or more cells.
118. The method of claim 117, further comprising isolating the multimeric polypeptide complex expressed from the one or more cells.
119. The method of claim 117 or 118, wherein the one or more cells comprise a plurality of cells, wherein the method further comprises selecting a cell of the plurality of cells that expresses the multimeric polypeptide complex.
120. The method of claim 119, wherein the selection of the cell from the plurality of cells is based on one or more members selected from (a) an amount or yield of the multimeric polypeptide complex produced by the cell, (b) a structural integrity of the multimeric polypeptide complex, and/or (c) a bioactivity of the multimeric polypeptide complex.
121. The method of claim 120, wherein, in (b), the structural integrity is characterized by subunit pairing, disulfide formation, or post-translational modification.
122. The method of claim 120 or 121, wherein, in (c), the bioactivity is characterized by cellular signaling activity or binding affinity against a target molecule.
123. [cite_start]A method for producing a multimeric polypeptide complex, the method comprising: introducing to a host cell: a first polynucleotide sequence encoding a first polypeptide subunit of the multimeric polypeptide complex operably coupled to a first promoter unit; and a second polynucleotide sequence encoding the first polypeptide subunit of the multimeric polypeptide complex operably coupled to a second and different promoter unit, and modulating exposure of the cell to a first light comprising a first wavelength or a wavelength range, wherein the first light is sufficient to effect expression level of the first polypeptide subunit. [cite: 1981-1987]
124. The method of claim 123, wherein the first promoter unit comprises an optogenetic promoter unit.
125. The method of claim 123 or 124, wherein the second promoter unit comprises a constitutive promoter.
126. [cite_start]A method for producing a multimeric polypeptide complex, the method comprising: introducing to a host cell: a first polynucleotide sequence encoding a first polypeptide subunit of the multimeric polypeptide complex operably coupled to a first optogenetic promoter unit; a second polynucleotide sequence encoding the first polypeptide subunit of the multimeric polypeptide complex operably coupled to a constitutive promoter; and a third polynucleotide sequence encoding a second polypeptide subunit of the multimeric polypeptide complex operably coupled to a promoter unit, and modulating exposure of the cell to a first light comprising a first wavelength or a wavelength range, wherein the first light is sufficient to effect expression level of the first polypeptide subunit. [cite: 1990-2000]
127. The method of claim any one of claims 123-126, wherein the promoter unit of the third polynucleotide sequence is a constitutive promoter.
128. The system of claim 127, wherein the promoter unit of the third polynucleotide sequence is a second optogenetic promoter unit.
129. [cite_start]A method for producing a multimeric polypeptide complex, the method comprising: introducing to a host cell: a first polynucleotide sequence encoding a first polypeptide subunit of the multimeric polypeptide complex operably coupled to a first optogenetic promoter unit; and a second polynucleotide sequence encoding a second polypeptide subunit of the multimeric polypeptide complex operably coupled to a second optogenetic promoter unit; modulating exposure of the cell to a first light comprising a first wavelength or a wavelength range, wherein the first light is sufficient to effect expression level of the first polypeptide subunit; and/or modulating exposure of the cell to a second light comprising a second wavelength or a wavelength range, wherein the second light is sufficient to effect expression level of the second polypeptide subunit. [cite: 2003-2010]
130. The method of any one of claims 123-129, wherein the modulating comprises initiating the exposure of the cell to the first light and/or the second light.
131. The method of any one of claims 123-129, wherein the modulating comprises terminating the exposure of the cell to the first light and/or the second light.
132. The method of any one of claims 123-129, wherein the modulating comprises changing one or more illumination parameters of the first light and/or the second light while the cell is under exposure to the first light and/or the second light.
133. The method of any one of the preceding claims, each optogenetic promoter unit comprises a DNA recognition sequence.
134. The method of any one of the preceding claims, wherein each optogenetic promoter unit comprises a promoter.
135. The method of claim 134, wherein the promoter comprises a minimal promoter.
136. The method of claim 135, wherein the minimal promoter is operably linked to the DNA recognition sequence.
137. The method of any one of the preceding claims, wherein the cell further comprises one or more light-controllable transcriptional regulators that interact (e.g., directly or indirectly) with the DNA recognition sequence of the first optogenetic promoter unit and/or the second optogenetic promoter unit.
138. The method of claim 137, wherein the first light or the second light is sufficient to regulate the interaction of the one or more light-controllable transcriptional regulators with the DNA binding region of the first optogenetic promoter unit and/or the second optogenetic promoter unit to control the expression of the first polypeptide subunit and/or the expression of the second polypeptide subunit.
139. The method of claim 137 or 138, wherein the one or more light-controllable transcriptional regulators are one or more light-controllable transcriptional activators or one or more light-controllable transcriptional repressors.
140. The method of claim 139, wherein the one or more light-controllable transcriptional activators comprise the light-controllable protein coupled to (e.g., directly or indirectly) a transcriptional activator.
141. The method of claim 140, wherein initiating the exposure of the cell to the first light or the second light induces the light-controllable transcriptional activator to bind to and activate the first optogenetic promoter unit or the second optogenetic promoter unit, thereby increasing the expression of the first polypeptide subunit or the second polypeptide subunit.
142. The method of claim 140 or 141, wherein initiating the exposure of the cell to the first light or the second light induces the light-controllable transcriptional activator to dissociate from the first optogenetic promoter unit or the second optogenetic promoter unit, thereby decreasing or terminating the expression of the first polypeptide subunit or the second polypeptide subunit.
143. The method of claim 139, wherein the one or more light-controllable transcriptional repressors comprise the light-controllable protein coupled to (e.g., directly or indirectly) a transcriptional repressor.
144. The method of claim 143, wherein initiating the exposure of the cell to the first light or the second light induces the light-controllable transcriptional repressor to bind to and repress the first optogenetic promoter unit or the second optogenetic promoter unit, thereby decreasing or terminating the expression of the first polypeptide subunit or the second polypeptide subunit.
145. The method of claim 143or 144, wherein initiating the exposure of the cell to the light induces the light-controllable transcriptional repressor to dissociate from the first optogenetic promoter unit or the second optogenetic promoter unit, thereby causing expression of the first polypeptide subunit or the second polypeptide subunit.
146. A multimeric polypeptide complex produced by the system of any one of claims 1-109, the cell of any one of claims 110-114, or the methods of any one of claims 117-145.
147. An antibody produced by the system of any one of claims 1-109, the cell of any one of claims 110-114, or the methods of any one of claims 117-145.

---

# Abstract

Provided herein are methods and compositions for complex molecule (e.g. multimeric polypeptide) subunit expression. By integrating optogenetic and constitutive expression systems with a combinatorial barcoded vector design, the present disclosure enable the optimization and fine-tuning of specific subunit expression levels. These advancements facilitate enhanced regulatory control over gene expression, thereby improving the efficiency and reliability of producing complex molecules for various biotechnological and therapeutic applications.

---

# Drawings

**FIG. 1A:** Depicts vectors Fc-1, Fc-2, Fc-3, Fab-1, Fab-2, and Fab-3 with Selection-1 and Selection-2 markers and barcodes 1-6.

**FIG. 1B:** Depicts pool combinations (e.g., Fc-1 + Fab-1) allowing for controlling HC1 and LC1 bottlenecks.

**FIG. 2:** Depicts vectors including Fc-1 through Fc-4 and Fab-1 through Fab-4 with associated selection markers and barcodes.

**FIG. 3:** Depicts vectors Fc-1 through Fc-4 and Fab-1 through Fab-4 with associated selection markers and barcodes.

**FIG. 4:** Depicts vectors with Opto-TA (Short activation time binds to blue promoter) and Opto-TA (long activation time binds to red promoter).

**FIG. 5A:** Diagram showing transcriptional activator, light-heterodimerizing domain 1, light-heterodimerizing domain 2, DNA binding domain, and light response.

**FIG. 5B:** Diagram showing transcriptional activator, light-homodimerizing domain, DNA binding domain, and light response.

**FIG. 6A:** Diagram showing light-dissociating domain 1, light-dissociating domain 2, DNA binding domain, and gene expression control.

**FIG. 6B:** Diagram showing light-dissociating domain, DNA binding domain, and gene expression control.

**FIG. 7A:** Diagram showing light uncaging domain, caged nuclear import signal, nuclear export signal, and transcriptional activator translocation.

**FIG. 7B:** Diagram showing light uncaging domain, caged nuclear export signal, nuclear import signal, and transcriptional activator translocation.

**FIG. 8A:** Diagram showing transcriptional repressor, light-heterodimerizing domains, constitutive promoter, and gene repression.

**FIG. 8B:** Diagram showing transcriptional repressor, light-homodimerizing domain, constitutive promoter, and gene repression.

**FIG. 9A:** Diagram showing light-dissociating domains and gene repression control.

**FIG. 9B:** Diagram showing light-dissociating domain and gene repression control.

**FIG. 10A:** Diagram showing light uncaging domain, caged nuclear import signal, nuclear export signal, and transcriptional repressor translocation.

**FIG. 10B:** Diagram showing light uncaging domain, caged nuclear export signal, nuclear import signal, and transcriptional repressor translocation.

---

# Power of Attorney

**Transmittal for Power of Attorney to One or More Registered Practitioners**
* **Application Number:** Not Yet Assigned
* **Filing Date:** Herewith
* **First Named Inventor:** Victor JONES
* **Title:** COMPOSITIONS, METHODS, AND SYSTEMS FOR CONTROLLING COMPLEX MOLECULE SUBUNIT EXPRESSION
* **Attorney Docket Number:** 60885-756.101
* **Signature:** /In Young Choi/
* **Name:** In Young Choi
* **Registration Number:** 80,724
* **Date:** 2025-10-02

**Power of Attorney by Applicant**
* **Customer Number:** 21971
* **Applicant Name:** Prolific Machines Inc.
* **Signer:** Deniz KENT, Co-Founder & CEO